Randhawa Simrat 4

What Happened
Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics (DNTH), exercised a total of 26,530 option-based derivative awards and immediately sold the same 26,530 shares in open-market transactions on June 1, 2026. The exercises cost approximately $500,205 in aggregate (breakdown below) and the open-market sales generated about $2,404,077 in gross proceeds. These transactions were executed pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 2, 2026 (timely).
• Options exercised (acquired): 26,530 shares total
  • 3,998 @ $8.44 = $33,743
  • 6,908 @ $17.88 = $123,515
  • 6,249 @ $21.77 = $136,041
  • 9,375 @ $22.07 = $206,906
  • Total exercise cost ≈ $500,205
• Open-market sales (disposed): 26,530 shares total for ≈ $2,404,077
  • 5,428 shares — weighted avg $89.72 (range $89.17–$90.16) — $487,000 (F2)
  • 16,943 shares — weighted avg $90.72 (range $90.17–$91.15) — $1,537,069 (F3)
  • 4,159 shares — weighted avg $91.37 (range $91.17–$91.96) — $380,008 (F4)
• Filing notes: Transaction executed under a Rule 10b5-1 trading plan (F1). Several footnotes (F5–F8) describe vesting schedules for the related option awards. The filing does not specify shares owned after the transactions in the provided summary.
• Transaction codes: M = option exercise/conversion; S = open-market sale.

Context
This was an exercise of stock options followed by immediate open-market sales — effectively a cashless exercise where the exercised shares were sold. The use of a Rule 10b5-1 plan means the sales were pre-specified and likely automated under plan terms; such sales are often routine and do not by themselves indicate a view about the company’s prospects. All figures above are from the Form 4; motivations are not stated.